LONDON, January 30, 2013 /PRNewswire/ --
EmergingGrowth.com, a leading digital financial media company, discusses Sunesis Pharmaceuticals, Amgen, Inc., Gilead Sciences and Biogen Idec, Inc.
The pharmaceutical sector is a very lucrative and competitive industry. And for emerging growth companies, it is difficult to make a meaningful impact in this cutthroat industry.
Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) has built a highly experienced cancer drug development organization committed to advancing its lead product candidate, Vosaroxin, to improve the lives of people with cancer.
Sunesis Pharmaceuticals' work translates to a rosy top line as demonstrated by the $25 million it earned from a previously announced royalty purchase agreement with Royalty Pharma. It took possession of $15 million from the second tranche of a 2011 venture loan facility. It raised $17.3 million from the sale of 3.6 million shares of common stock and $1.4 million from the gross exercise of 0.6 million warrants to purchase common stock. This not only shows that Sunesis is able to raise capital for research purposes, but it also represents the company's keen interest in creating shareholder value.
The company is in the follow-up stage of trials of Vosaroxin, having completed a Phase 2 trial in ovarian cancer patients in 2010. However, broader market tailwinds will propel the company through the next decade. Vosaroxin is a first-in-class anticancer quinolone derivative, a class of compounds that has not been used previously for the treatment of cancer. As of now, notable breakthroughs are being made with the drug, particularly as complete remissions have been observed in patients treated with Vosaroxin in combination with Cytarabine.
Just like its bigger competitors, Amgen Inc. (NASDAQ: AMGN) and Gilead Sciences Inc. (NASDAQ: GILD), Sunesis also wants to make a big impact. To ensure this, it has entered into a collaboration agreement with Millennium Pharmaceuticals for the development of Sunesis' inhibitor. It also announced the license of the company's LFA-1 inhibitor program to SARcode Corporation, a privately held bio-pharmaceutical company. In addition, it has announced a collaboration agreement with Biogen Idec Inc. (NASDAQ: BIIB) to discover, develop, and commercialize inhibitors of Raf kinase and up to five additional oncology kinase targets.
All these developments will signal the market's gravitation toward Sunesis products. Considering that ovarian cancer is the eighth most common cancer among women, it would be accurate to say that vosaroxin will be relevant in the market. In addition, the future promise of FDA approval brightens the long-term picture and promises longevity. With a market capitalization of $226 million and a 52-week range $1.29 - $6.85 (the stock is currently trading close to its high at around $4), it would be accurate to say that Sunesis Pharmaceuticals will gain tremendous value in the next few years.
NEW: Feature your company on EmergingGrowth.com. Find out how by filling out our referral form here: http://emerginggrowth.com/recommend-a-company-to-feature-on-emerging-growth
By offering 100% original and unmatched content by the best financial reporters, writers and bloggers in the business, EmergingGrowth.com is emerging as a leading digital financial media portal. Its services provide users, subscribers and advertisers with a variety of content and tools through a range of online, social media, mobile and other mobile outlets.
Since its inception, EmergingGrowth.com has distinguished itself from other financial media companies with its sly approach to reading between the lines in order to locate that needle in the haystack. Sign up today to see what EmergingGrowth.com has to offer.
Join our LinkedIn Group… http://www.linkedin.com/groups/?gid=4650356&trk=hb_side_g
Like us on Facebook... http://www.facebook.com/pages/EmergingGrowthcom/474647062557938
Copyright©2012 PR Newswire.
All rights reserved